Akademik Veri Yönetim Sistemi
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, cilt.30, sa.3, ss.914-918, 2010 (SCI-Expanded)
Objective: The aim of this study was to collect the data of low-risk febrile neutropenic patients with solid tumors orally treated with amoxicillin/clavulanate and ciprofloxacin. Material and Methods: Adult patients with solid tumors who were treated with conventional dose of chemotherapy, presented with fever (axillary temperature 38 degrees C on two occasions or 38.3 degrees C on a single occasion) and neutropenia (absolute neutrophil count, 500 cells/mL), and met low risk criteria (above 20) according to "The Multinational Association for Supportive Care in Cancer" (MASCC) were eligible for this study. All patients received empirical therapy with oral ciprofloxacin (500 mg twice daily) plus amoxicillin/clavulanate (1000 mg, three times daily). Results: Twenty-one episodes of febrile neutropenia in 20 patients (including two episodes of a patient with lung cancer) were studied retrospectively. The mean age was 55.5 years (range, 30 to 77 years), and most were females (70%). On the initial evaluation, two of these patients had mild diarrhea and the others had a fever of unknown origin. Treatment was successful in 76% of the episodes. Twenty-seven percent of episodes required modification of initial antibiotic therapy to intravenous administration of antibiotics. No death was observed due to the febrile neutropenic episode. Conclusion: In low-risk patients with solid tumors who have fever and granulocytopenia, oral therapy with ciprofloxacin plus amoxicillin/clavulanate seems to be an effective alternative approach for empirical therapy.